RedHill Biopharma Sells Talicia Business to Apotex Health
RedHill Biopharma has agreed to sell its stake in the antibiotic treatment Talicia to a subsidiary of Apotex Health for $18 million upfront, with potential additional payments of up to $35 million based on worldwide net sales milestones. The deal involves transferring RedHill's 70% interest in Talicia and is expected to provide financial resources that will allow the company to expand its gastrointestinal commercial operations. The transaction aims to strengthen RedHill’s portfolio by enabling further growth through FDA-approved product opportunities, accelerating progress toward operational profitability. This move reflects a strategic shift for RedHill as it focuses on scaling up its core business and leveraging new therapeutic options in the GI space.
Tickers: $RDHL
Topics: Commercial strategy Divestiture FDA-approved products M&A